What it's for (Indications)
- Alfacalcidol, a potent vitamin D analogue, is primarily indicated for the management and treatment of various conditions characterized by disturbances in calcium and phosphate metabolism, particularly when conventional vitamin D therapies are ineffective or contraindicated.
- Its main applications include the treatment of renal osteodystrophy in patients with chronic kidney disease (CKD), where impaired renal 1α-hydroxylation prevents the conversion of native vitamin D to its active form, calcitriol.
- It is also extensively used in the management of hypoparathyroidism (e.
- g.
- , post-surgical, idiopathic, pseudohypoparathyroidism) to normalize serum calcium levels.
- Other key indications encompass rickets and osteomalacia that are resistant to vitamin D, as well as certain forms of osteoporosis, especially those associated with underlying vitamin D metabolic disorders or secondary hyperparathyroidism.
- Furthermore, alfacalcidol may be utilized in specific instances of neonatal hypocalcemia or in patients requiring active vitamin D metabolites due to genetic disorders affecting vitamin D metabolism.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of alfacalcidol must be carefully individualized and adjusted based on the patient's biochemical responses, particularly serum calcium, phosphate, and parathyroid hormone (PTH) levels. The goal of therapy is to normalize serum calcium and phosphate levels without inducing hypercalcemia. For adults, an initial dose typically ranges from 0.25 to 1.0 microgram daily. In pediatric patients, the initial dose is often calculated based on body weight, commonly starting at 0.01 to 0.05 microgram/kg/day. Subsequent dose adjustments should be made at intervals of 2-4 weeks, or as clinically indicated, depending on the monitoring results. Close and frequent monitoring of serum calcium and phosphate levels (e.g., twice weekly initially, then monthly or quarterly for maintenance) is crucial throughout the treatment period to prevent hypercalcemia and ensure therapeutic efficacy. The dose should be reduced or temporarily discontinued if hypercalcemia or hyperphosphatemia occurs, and reinitiated at a lower dose once these levels normalize. |
Safety & Warnings
Common Side Effects
- The most significant and common adverse effect associated with alfacalcidol therapy is hypercalcemia, which can manifest with a range of symptoms from mild to severe.
- Early symptoms of hypercalcemia often include gastrointestinal disturbances such as nausea, vomiting, constipation, and abdominal pain.
- Patients may also experience polyuria (increased urination), polydipsia (increased thirst), anorexia, muscle weakness, headache, lethargy, fatigue, and confusion.
- If hypercalcemia is prolonged or severe, it can lead to more serious complications including nephrocalcinosis, kidney stones (urolithiasis), impaired renal function, and cardiovascular effects such as cardiac arrhythmias, particularly in individuals concurrently receiving digitalis glycosides.
- Less commonly reported side effects include skin rash, pruritus, and local irritation at the injection site if administered parenterally.
- Regular monitoring of serum calcium and phosphate levels is imperative to detect and manage these adverse effects promptly.
Serious Warnings
- Black Box Warning: Alfacalcidol does not carry a formal FDA Black Box Warning. However, clinicians and patients must be acutely aware of the **Serious Warning** regarding the profound and potentially life-threatening risk of hypercalcemia associated with its use. Hypercalcemia is the primary dose-limiting toxicity and can lead to severe adverse events including acute renal failure, nephrocalcinosis, and extensive ectopic calcification in soft tissues and vasculature, which can have irreversible consequences. Furthermore, hypercalcemia can precipitate serious cardiac arrhythmias, especially in patients concomitantly receiving digitalis glycosides. Rigorous and frequent monitoring of serum calcium levels, often several times weekly during initiation and dose titration, and regularly thereafter, is absolutely essential to mitigate this risk. Patients must be thoroughly educated to recognize and immediately report symptoms of hypercalcemia such as nausea, vomiting, polyuria, polydipsia, headache, and weakness. Prompt dose reduction or temporary discontinuation of alfacalcidol, along with measures to reduce serum calcium, is imperative upon detection of hypercalcemia to prevent grave complications. Concomitant use of calcium supplements, thiazide diuretics, or other vitamin D compounds significantly increases this risk and requires heightened vigilance.
- Extreme caution is warranted during alfacalcidol therapy due to the narrow therapeutic window and the significant risk of hypercalcemia, which necessitates frequent and meticulous monitoring of serum calcium and phosphate levels.
- Patients should be thoroughly educated on the symptoms of hypercalcemia (e.
- g.
- , nausea, vomiting, polyuria, polydipsia, weakness) and instructed to report any such signs immediately.
- Special vigilance is required in patients with impaired renal function, as they may be more susceptible to hypercalcemia and hyperphosphatemia.
- Concomitant administration of other vitamin D derivatives, calcium supplements, or thiazide diuretics can significantly increase the risk of hypercalcemia and must be managed with extreme caution and increased monitoring.
- Digitalis-treated patients are at an elevated risk, as hypercalcemia can precipitate serious cardiac arrhythmias.
- Monitoring for signs of ectopic calcification, especially in the kidneys and soft tissues, is also important.
- Use in pregnancy and lactation should only occur if the potential benefit justifies the potential risk to the fetus or infant, as safety data are limited.
How it Works (Mechanism of Action)
Alfacalcidol (1α-hydroxyvitamin D3) is a synthetic analogue of calcitriol, the active form of vitamin D. Unlike native vitamin D (cholecalciferol or ergocalciferol), alfacalcidol does not require renal 1α-hydroxylation to become biologically active. Instead, it undergoes a rapid and efficient hydroxylation in the liver at the 25-position to form 1,25-dihydroxyvitamin D3 (calcitriol). This characteristic makes it particularly useful in patients with chronic kidney disease or other conditions where renal 1α-hydroxylase activity is impaired. The resulting calcitriol exerts its actions by binding to the vitamin D receptor (VDR) present in various target tissues. This binding leads to a cascade of effects including increased intestinal absorption of both calcium and phosphate, modulation of bone remodeling and mineralization, and suppression of parathyroid hormone (PTH) secretion, thereby ameliorating secondary hyperparathyroidism. By directly providing a precursor that only requires hepatic activation, alfacalcidol effectively bypasses the impaired renal activation step.